Details for Patent: 6,632,842

US Patent 6,632,842: Scope, Claim Construction, and US Patent Landscape

What does US 6,632,842 claim in plain technical terms?

US Patent 6,632,842 claims a patient-use method for reducing medication error and improving therapeutic compliance in COPD patients, paired with a specific fixed-dose, prefilled, benzalkonium-chloride-free albuterol/ipratropium nebulization solution and prescribing information containing defined contraindications and adverse-reaction content.

The core claim architecture is consistent across the independent claim(s) you provided:

1. Administration step using a single dispensing container that is prefilled with a defined aqueous inhalation solution.
2. The solution is therapeutically effective after 12 months at 25°C (stability requirement).
3. The method includes providing prescribing information.
4. The prescribing information includes specific contraindication content and specific adverse-reaction content (both content-driven limitations).
5. Dependent claim adds detailed dose frequency and allowed extras plus expanded adverse event lists.

This is not a composition-use claim in isolation. It is a method of care claim that tightly couples:

• the container format
• the drug formulation definition
• and labeling/content constraints.

Claim-by-claim scope (based on the provided claim text)

Claim 1: Prefilled single container + label content tied to COPD nebulization

Claim 1 recites a method for individuals with COPD, comprising:

(a) Administration using a single dispensing container

• Container is prefilled with about 3 mL of sterile, benzalkonium chloride-free, premixed, premeasured aqueous inhalation solution.
• The solution contains a unit dose of:
  • Albuterol ~2.5 mg
  • Ipratropium bromide ~0.5 mg
• The solution is:
  • suitable for nebulization
  • stable such that it is therapeutically effective after 12 months at 25°C

(b) Provide prescribing information

• Prescribing information must include:
  • dosage
  • administration
  • contraindication
  • adverse reaction information specific to the inhalation solution in the container

(c) Contraindication limitation

• Contraindication info indicates the solution is contraindicated for humans with hypersensitivity to atropine and derivatives thereof.

(d) Adverse reaction limitation

• Adverse reaction info indicates:
  • lung disease, bronchitis, diarrhea, and pharyngitis may occur after administration.

Practical scope implication

• A party practicing the method must use the defined prefilled solution and must provide labeling that contains at least the claimed contraindication and adverse-reaction disclosures.

Claim 2: Dependent claim adds dose regimen + expanded adverse and hypersensitivity categories

Claim 2 depends from claim 1 and further requires that prescribing information includes:

Immediate hypersensitivity reactions may occur

• Hypersensitivity includes:
  • urticaria
  • angioedema
  • rash
  • pruritis
  • oropharyngeal edema
  • bronchospasm
  • anaphylaxis

Additional adverse reaction list

• The adverse reaction information indicates that:
  • precipitation or worsening of narrow-angle glaucoma
  • acute eye pain
  • blurred vision
  • paradoxical bronchospasm
  • pneumonia
  • plus multiple other events including (from your text):
  • dyspepsia, wheezing, exacerbation of COPD symptoms, drowsiness, aching, flushing
  • upper respiratory tract infection, palpitations, taste perversion
  • elevated heart rate, sinusitis, back pain, sore throat, constipation
• Also includes a list element tying one or more adverse reactions to administration.

Practical scope implication

• Claim 2 is labeling-content intensive. Even if a competitor uses the same clinical regimen and container, differences in labeling language or event inclusion could matter.

Claim 3 (as provided): Prefilled formulation definition expanded + dosage schedule explicitly limited

The text you provided after claim 2 reads like a second independent claim or an additional claim (commonly drafted similarly). It includes additional formulation and dosing limitations.

Key added formulation elements include:

• Solution components include:
  • water
  • edetate disodium
  • sodium chloride
  • an acid to adjust pH between about 3 and 4
• Drug potency expressed as:
  • Albuterol ~2.50 mg/3 mL
  • Ipratropium bromide ~0.5 mg/3 mL
• Benzalkonium chloride-free remains required.
• Stability remains 12 months at 25°C.
• The method includes prescribing information content including efficacy in addition to dosage/admin and adverse/contraindications.
• Dose regimen explicitly limited:
  • one container (3 mL) administered 4 times per day by nebulization
  • up to 2 additional doses allowed per day, if needed

Additional contraindication remains:

• hypersensitivity to atropine and derivatives thereof.

Additional adverse reactions include both:

• immediate hypersensitivity reactions (urticaria, angioedema, rash, pruritis, oropharyngeal edema, bronchospasm, anaphylaxis)
• and expanded adverse events list including:
  • precipitation/worsening narrow-angle glaucoma
  • acute eye pain, blurred vision, paradoxical bronchospasm, wheezing
  • exacerbation of COPD symptoms
  • drowsiness, aching, flushing
  • URTI, palpitations, taste perversion, elevated heart rate
  • sinusitis, back pain, sore throat
  • plus an extended “one or more adverse reactions” set: chest pain, diarrhea, dyspepsia, nausea, leg cramps, bronchitis, lung disease, pharyngitis, pneumonia, urinary tract infection

Practical scope implication

• Claim 3 tightens formulation chemistry (pH 3-4, specific excipient set) and dosing schedule. It also requires label content to include broad adverse-event reporting.

What is the claim “center of gravity” for infringement and validity risk?

1) Prefilled, single-container format with fixed dose

The claim requires:

• a single dispensing container
• prefilled with ~3 mL
• containing fixed unit doses of albuterol and ipratropium.

A design-around that changes container format (e.g., multi-dose reservoir, separate vials that are mixed at point of care) typically avoids the “single dispensing container prefilled” limitation.

2) Formulation constraints: benzalkonium chloride-free + defined stability

• Benzalkonium chloride-free is explicit.
• Therapeutically effective after storage for 12 months at 25°C is explicit.

A competitor could potentially change preservative choice and still be COPD-relevant, but would miss the benzalkonium-chloride-free limitation.

3) Formulation constraints (in the “expanded” claim text): excipients and pH

In the third claim text you provided, the solution composition is narrowed to:

• water + edetate disodium + sodium chloride + an acid to set pH 3-4.

That is a stronger constraint than “aqueous inhalation solution” and is more likely to create product-by-product infringement sensitivity.

4) Label content limitations (the strongest litigation lever)

This patent’s method hinges on prescribing information including:

• contraindication for hypersensitivity to atropine and derivatives
• adverse-reaction categories and specific events (lung disease, bronchitis, diarrhea, pharyngitis in claim 1; expanded lists in claim 2 and the expanded claim text)

This makes the claims resemble “labeling-mandated” method claims. In enforcement and design-around strategies, label wording and content can become as important as formulation.

How does this sit within COPD nebulized albuterol/ipratropium IP strategy?

What the claims are trying to protect

US 6,632,842 targets an integrated “system”:

• fixed-dose albuterol/ipratropium nebulized solution
• in a prefilled single container
• plus labeling content aimed at medication-error reduction and compliance

That suggests the likely commercial context was packaging and labeling for a nebulized combined bronchodilator regimen rather than a purely chemical composition.

Where it can overlap with other IP buckets

For a landscape view, this claim sits at the intersection of:

1. Formulation patents for albuterol and ipratropium nebulization solutions (including preservatives/excipients and pH/stability).
2. Device and packaging patents for single-dose nebules (prefilled sterile containers, extractable/leachable controls, and dosing convenience).
3. Labeling and instruction-related IP (contraindication and adverse-event statement scope).
4. Fixed-dose combination patents (albuterol + ipratropium together for COPD symptom control).

Because your provided text is claim-language heavy on prescribing information, it is likely to differentiate from purely composition-only patents.

US patent landscape: likely zones of freedom-to-operate (FTO) and conflict

A practical landscape must be segmented by what parties would need to copy to land in the same claim boundaries:

Zone A: High conflict (close literal match)

Products/methods that:

• deliver albuterol 2.5 mg + ipratropium 0.5 mg per 3 mL nebulized dose
• are benzalkonium chloride-free
• remain stable for 12 months at 25°C
• use single prefilled containers (not unit dosing assembled elsewhere)
• include prescribing information content with the specific contraindication and adverse event categories

Zone B: Medium conflict (partial match)

• Same drugs and dosing but different packaging format (e.g., multi-dose reservoir, mixed at administration).
• Same general solution but different preservative system if the product is not benzalkonium-chloride-free.
• Similar formulation but pH/excipient differences if the “pH 3-4 + edetate disodium + sodium chloride + acid” limitation is asserted.

Zone C: Lower conflict

• Different unit-dose concentrations or different container volume.
• Different dosing cadence (if the 4x/day with up to 2 additional doses “if needed” limitation is asserted).
• Labeling content that omits or substantially changes the claimed adverse reaction categories.

What is the strategic significance of the stability and pH limitations?

Stability

The claim ties to:

• “therapeutically effective following storage for 12 months at 25°C.”

In an FTO setting, that creates:

• a compliance target for formulation engineering
• a potential evidentiary battlefield for product equivalence (stability studies, shelf-life justification).

pH 3-4 + excipient set

Where present, that limitation narrows to:

• pH in a specific window
• specific excipients: edetate disodium and sodium chloride
• “an acid to adjust pH” as the pH regulator

That makes “chemistry-only” design-around plausible by shifting pH or excipient package, but it must also preserve nebulization suitability and stability.

Claims vs. “method of reducing medication error”: what does that add to scope?

The “method of reducing medication error and enhancing therapeutic compliance” language functions as:

• the purpose framing of the method
• but, because the claim includes specific administration and prescribing information limitations, it is not purely aspirational.

In practical terms, the enforceable boundaries are the technical steps and labeling content, not the intent language.

Key takeaways

• US 6,632,842 is a labeling-driven, patient-method patent tethered to a specific prefilled nebulization unit dose for COPD: albuterol 2.5 mg + ipratropium 0.5 mg in ~3 mL, benzalkonium chloride-free, stable for 12 months at 25°C.
• The strongest differentiators for infringement and design-around are:
  • single dispensing container prefilled format
  • benzalkonium chloride-free + stability requirements
  • (in narrower claim text) pH 3-4 and excipient set
  • prescribing information content: contraindication to atropine/derivatives hypersensitivity and specific adverse reaction event categories/lists.
• The landscape risk concentrates around nebules for COPD combined therapy where the same unit dose and labeling content are used.

FAQs

1) Is US 6,632,842 primarily a formulation patent or a device/packaging patent?

It is neither alone. It is a method claim that requires a specific prefilled nebulization solution in a single dispensing container, coupled to prescribing information content.

2) If a product uses the same drugs but different concentrations, does it still fall within the claims?

Not if it misses the claimed unit doses (albuterol ~2.5 mg and ipratropium ~0.5 mg in ~3 mL) and related formulation constraints.

3) How can competitors reduce infringement risk?

By altering one or more of the claim-critical elements: prefilled single container format, benzalkonium chloride-free status, stability, pH/excipient requirements (where recited), and especially prescribing information content tied to contraindications/adverse reactions.

4) Does the patent protect the act of nebulization itself?

It protects a method that includes administration with the specified prefilled container plus the act of providing prescribing information with defined content.

5) What claim elements are likely to matter most in litigation?

The evidentiary focus typically concentrates on whether the accused product:

• matches the unit-dose formulation and stability constraints, and
• whether its labeling and patient instructions include the claimed contraindications and adverse reaction categories.

References

[1] US Patent 6,632,842 (provided claim text: Claims 1-3 as quoted by user).